We are live on
!
Find out more
BGI
B Group Inc Portfolio holdings
AUM
$135M
1-Year Est. Return
80%
This Fund
S&P 500
This Quarter
Est. Return
+9.51%
1 Year Est. Return
+80%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$117M
AUM Growth
-$46.9M
(-29%)
Cap. Flow
-$50.5M
Cap. Flow
% of AUM
-43.28%
Top 10 Holdings %
Top 10 Hldgs %
92.29%
Holding
20
New
2
Increased
12
Reduced
3
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Iovance Biotherapeutics
IOVA
|
+$2.62M |
| 2 |
Assembly Biosciences
ASMB
|
+$1.95M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
+$1.66M |
| 4 |
BioNTech
BNTX
|
+$1.29M |
| 5 |
Praxis Precision Medicines
PRAX
|
+$1.19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$6.69M |
| 2 |
AKRO
Akero Therapeutics
AKRO
|
+$742K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
ADMA Biologics
ADMA
$2.02B
| $46M | 39.39% |
2,317,542
+30,000
| +1% | +$519K |
|
|
2
Insmed
INSM
$23.5B
| $20M | 17.16% |
262,500
-87,500
| -25% | -$6.69M |
|
3
Zai Lab
ZLAB
$2.28B
| $14.5M | 12.38% |
400,000
| – | – |
|
|
AKRO
4
DELISTED
Akero Therapeutics
AKRO
| $9.82M | 8.41% |
242,500
-17,500
| -7% | -$742K |
|
|
5
Iovance Biotherapeutics
IOVA
$2.23B
| $5M | 4.28% |
1,500,000
+508,000
| +51% | +$2.62M |
|
|
CLLS
6
Cellectis
CLLS
$265M
| $4.04M | 3.46% |
3,256,501
+175,000
| +6% | +$259K |
|
7
Aura Biosciences
AURA
$723M
| $2.77M | 2.37% |
472,576
| – | – |
|
8
Sight Sciences
SGHT
$274M
| $2M | 1.71% |
833,600
+204,230
| +32% | +$575K |
|
|
9
Assembly Biosciences
ASMB
$531M
| $1.91M | 1.64% |
200,000
+149,349
| +295% | +$1.95M |
|
10
Taysha Gene Therapies
TSHA
$1.71B
| $1.75M | 1.5% |
1,255,556
+290,000
| +30% | +$485K |
|
|
11
Ultragenyx Pharmaceutical
RARE
$2.88B
| $1.72M | 1.47% |
47,500
+39,904
| +525% | +$1.66M |
|
|
12
BioNTech
BNTX
$23.1B
| $1.37M | 1.17% |
15,000
+11,500
| +329% | +$1.29M |
|
|
13
CALL
Ultragenyx Pharmaceutical
RARE
$2.88B
| $1.36M | 1.17% |
37,600
+8,100
| +27% | +$337K |
|
14
Spyre Therapeutics
SYRE
$8.7B
| $1.13M | 0.97% |
70,000
+20,000
| +40% | +$416K |
|
15
Apogee Therapeutics
APGE
$10.1B
| $1.12M | 0.96% |
30,000
+15,000
| +100% | +$580K |
|
|
16
Praxis Precision Medicines
PRAX
$8.77B
| $720K | 0.62% |
+19,000
| New | +$1.19M |
|
|
ETNB
17
DELISTED
89bio
ETNB
| $695K | 0.6% |
+95,623
| New | +$836K |
|
|
ORKA
18
Oruka Therapeutics
ORKA
$5.59B
| $597K | 0.51% |
58,215
+38,215
| +191% | +$477K |
|
19
PUT
Corvus Pharmaceuticals
CRVS
$1.25B
| $286K | 0.25% |
90,000
-10,000
| -10% | -$47.1K |
|
20
PUT
Invesco QQQ Trust
QQQ
$466B
| – | – |
-110,000
| Closed | -$56.2M |
|
Similar funds
UOP
ICM
EC
AV
FA
GEH
SA
SCM
B Group Inc's Q1 2025 Portfolio in Review
As of Q1 2025, B Group Inc held 20 positions worth $117M, down 29% from $164M the previous quarter. Its ten largest holdings account for 92% of the portfolio.
B Group Inc withdrew a net $50.5M in Q1 2025, closing 1 position and reducing 3 holdings. Its largest reduction was Insmed, cutting an estimated $6.69M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 65% a quarter earlier.
Against the trend, B Group Inc opened a new position in Praxis Precision Medicines worth $720K.
- B Group Inc's largest Q1 2025 buy was Praxis Precision Medicines: 19,000 shares worth $720K.
- B Group Inc added most to Iovance Biotherapeutics in Q1 2025, an estimated $2.62M increase.
- B Group Inc's biggest Q1 2025 reduction was Insmed, cutting an estimated $6.69M.
- B Group Inc's ten largest holdings make up 92% of its $117M portfolio in Q1 2025.
- B Group Inc opened 2 new positions and closed 1 in Q1 2025.
- B Group Inc's portfolio value fell 29% quarter-over-quarter to $117M.
Based on B Group Inc's 13F filing for Q1 2025, filed 15 May 2025.